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suggest that the community pharmacists in Pakistan do have concerns regarding 
their present clinical and professional role. Besides, this study also suggested that 
community pharmacists need to be more proactive and professional in collaboration 
with other health care professionals.
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OBJECTIVES: To investigate hospital pharmacists’ Knowledge, Attitude and 
Perceptions (KAP) regarding pharmacists-led interventions to reduce Adverse Drug 
Reactions (ADRs), Drug Interactions (DIs), and Pharmaceutical Care Issues (PCIs) 
towards better pharmaceutical care planning in Pakistan. METHODS: A prospective, 
cross-sectional and self-administered questionnaire based study was conducted in 
tertiary care public hospitals in Pakistan. Only registered hospital pharmacists were 
approached to obtain data regarding their KAP towards pharmacists-led interven-
tions to reduce ADRs, DIs, and PCIs towards better pharmaceutical care planning. All 
obtained data were analyzed using descriptive and inferential statistics. RESULTS: 
More than two thirds of the hospital pharmacists (75%) rated physicians as the first 
person to contact in case of any ADRs, DIs, and PCIs. Nevertheless, very poor KAP 
was observed towards pharmacist’s professional role in addressing ADRs, DIs, and 
PCIs (79%). Unexpectedly, 42% of them were not having appropriate knowledge 
towards pharmacists’ role in addressing ADRs, DIs, and PCIs in PCP (79%). A total of 
72.1% reported that they are familiar with the procedure of reporting ADRs. A total 
of 89.1% of the respondents agreed that safe, effective and patient-centered PCP 
plays an important role in patient safety and professional healthcare. In multivari-
ate logistic regression, statistical correlations showed that gender and age were the 
persuasive predictors for the studied model. CONCLUSIONS: The findings from this 
study endorse that the knowledge of hospital pharmacists in Pakistan regarding 
their role to reduce ADRs, DIs, and PCIs towards better pharmaceutical care plan-
ning was not satisfactory. Their attitude towards learning of latest methods and 
procedures to address ADRs, DIs, and PCIs was satisfactory. However, pharmacists 
need to be more proactive and professional in playing their professional role towards 
better patient care.
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OBJECTIVES: We assessed trends in approvals of new molecular entities (NME) and 
new therapeutic biologic license applications (BLA) in the US in the period 1980-2014 
by country of incorporation of the sponsor company of the application. METHODS: 
Regulatory information for NMEs and BLA approved in the study period was derived 
from the FDA, and the country of incorporation of the sponsor companies at the date 
of drug approval was extracted from Lexis-Nexis, companies’ webpages and financial 
reports. Drugs were classified using the WHO anatomical therapeutic chemical clas-
sification system. Descriptive statistics and chi-square tests were conducted in the 
study. RESULTS: The FDA approved 103 BLA and 866 NME during the period 1980-2014. 
Five countries had an average of at least 1 BLA/NME approved per year during the 
study period: US (57.9% of all approvals), UK (10.6%), Switzerland (10.0%), Germany 
(7.1%), and Japan (3.7%). The percentage of drugs approved by US companies ranged 
from 65.9% for antiinfectives for systemic use to 38.9% for sensory organs. US com-
panies sponsored a higher number of BLA (76.7%) than NME (55.7%) (p< 0.001). Drugs 
approved by US companies varied from 62.7% in the 1980s, 56.6% in the 1990s, 58.2% in 
the 2000s, and 53.2% in the period 2010-2014. The therapeutic classes with the largest 
percentage of approvals for each country of incorporation were: dermatologicals in the 
UK (27.0% of all approvals), sensory organs in Switzerland (38.9%), respiratory system 
in Germany (18.4%), nervous system in Japan (9.4%), and genitourinary system and sex 
hormones in France (6.1%). US companies sponsored a larger percentage of orphan 
(64.8%) than non-orphan drugs (54.6%) (p< 0.001). CONCLUSIONS: Approximately 90% 
of all new drugs approved by the FDA were sponsored by companies incorporated 
in US, UK, Switzerland, Germany, and Japan, indicating that pharmaceutical R&D is 
concentrated in a few countries.
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OBJECTIVES: The Essential Medicine Policy (EMP) was implemented to improve 
the affordability of medicines and reduce patients’ economic burden in 2009 along 
with the new round of health care reform in China. This study is to evaluate the 
effects of EMP on patients’ health care utilization and spending. METHODS: Urban 
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OBJECTIVES: This research aims to examine whether minority and/or low-income 
patients are slower to stop use of a particular medical treatment when there is 
new evidence of safety risks. METHODS: We examine the demand response of 11 
chronic medications that received first-time major safety warnings (including black 
box warnings) from the Food and Drug Administration (FDA) between July 2006 -- 
December 2009. We restrict the sample to medications that experienced decreased 
utilization post-warning and followed patients who were users of at least one of the 
11 medications. Selected Medicare beneficiaries were 18 years or older (n = 549,645), 
drawn from a random 20% sample of Medicare Part D claims data. A pooled multi-
variate logistic regression was performed on the likelihood of these patients stop-
ping use post warning (defined as having no claims of the medication between 180 
-- 360 days post warnings), controlling for patient demographics, Medicare plan type, 
new user status (naive patients or not), medication and state fixed effects. RESULTS: 
Preliminary analyses suggest that Hispanics and blacks were more likely to stop tak-
ing a medication compared to whites (ORs= 1.160 and 1.122, respectively, p< 0.001). 
By contrast, Medicare beneficiaries eligible to receive medications at little or no 
cost, i.e. dual-eligibiles and those who received low income subsidies, were less 
likely to stop than non-subsidized beneficiaries (ORs = 0.790 and 0.792 respectively, 
p< 0.001). Users who initiated their medications within 6 months before the safety 
warnings were the most likely to stop use in the post-warning period (OR = 3.759, 
p< 0.001). CONCLUSIONS: The findings suggest that socio-economic status is associ-
ated with modestly longer delays in stopping drug therapy with recent medication 
safety warnings. Specifically, low-income patients who are subsidized beneficiaries 
are less likely to stop using medications that received safety warnings and therefore 
may be subject to greater harm from adverse drug effects.
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OBJECTIVES: Medication Guides are patient-directed, Food and Drug Administration 
(FDA)-approved labeling intended to provide risk and safe-use information for 
prescription medications in easy-to-read, lay language. They were introduced to 
help patients understand and manage risks and maximize benefit from products 
by aiding in decision-making and helping improve adherence to and appropri-
ate use of medications. This review was designed to assess whether patients are 
receiving medication guides per federal regulations and are able to use them as 
intended. METHODS: Knowledge, Attitudes, and Behavior (KAB) survey results in 
a heterogeneous sample of FDA-mandated REMS were reviewed to assess under-
standing of key risk messages (KRM) and receipt, reading, and understanding of 
medication guides. Results were calculated individually and compared across 
surveys. RESULTS: The review includes results from 36 patient KAB surveys for 
products in 8 therapeutic areas. Sample sizes ranged from 10-628 respondents per 
survey. Receipt: Median 89.3% (range 58.1-99.6%) of respondents reported receiving a 
medication guide. Reading: Median 93.1% (range 77.0-100.0%) of respondents report-
ing receiving a medication guide reported reading at least some of it. Understanding: 
Median 93.7% (range 36.8-100.0%) of respondents reported understanding all or 
most of what they read in the medication guide. Median 98.3% (range 64.6-100.0%) 
of respondents reported they understood all or most of what they read after having 
someone explain the information. In an objective assessment of understanding KRM 
of medication guides, median 72.4% (range 1.2-100.0%) of respondents answered 
questions correctly. CONCLUSIONS: This review demonstrates the inconsistency of 
usability of medication guides for the purposes intended as shown by the range of 
responses, particularly objective assessment of KRM understanding. Usability may 
be limited by incomplete distribution and inadequate risk communication. Data 
will be presented to discuss differences in reported and demonstrated understand-
ing and possible reasons why patients may be unable to use medication guides as 
they are intended.
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OBJECTIVES: To investigate community pharmacists’ perception towards inter 
professional learning (IPL), continue professional development (CPD) programs 
and their current clinical and professional role towards patient care in Pakistan’s 
health care system. METHODS: This study was conducted on community phar-
macists from different cities of the biggest province of Pakistan, the Punjab. Data 
was collected by convenient sampling method from all major cities of the province. 
Different statistical tests were used to analyze the obtained data. RESULTS: Around 
93.9% of the community pharmacists were involved in prescription filling, refilling 
and patient counseling in the Punjab, Pakistan. They all were willing to take part 
in IPL, CPDs and patient safety programs but majority of the pharmacist (82.8%) 
conveyed that their current role is more focusing towards the store manager, buy-
ing and selling of the medicines and inventory control. Surprisingly, 75% of them 
were not aware about IPL and CPDs. CONCLUSIONS: The findings from this study 
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scheme, prices of brand-name and generic drugs are to be set to the same level 
after the patent expires. METHODS: The data used for this study were extracted 
from the National Health Insurance Claims database. We established a monthly 
panel dataset pertaining to pharmaceutical consumption between January 2011 
and June 2013 (30 months). Proxies of market competition were considered as 
dependent variables such as price dispersion, market share of originators and 
relative ratio of utilization (originator/generics). Independent variables including 
policy effect, number of generic drugs, vintages of the first generic drugs, month 
for new generic entry and market value. RESULTS: The new pricing policy has 
resulted in no competition mechanism. Rather the policy shows more favorable 
to originators than generic drugs. Price dispersion has significantly decreased 
to 0.92 after the new pricing regulations. Market share of the originators has not 
significantly changed. However, originator-to-generic utilization ratio significantly 
increased to 6.12 (p< 0.001) after the new policy. This study offers different results 
to the government’s intention. CONCLUSIONS: Price competition cannot be suc-
cessfully achievable unless demand-side measures are combined. To lower prices, 
the bigger market share should be delivered through demand-side measures such 
as the reference pricing or compulsory substitution to lowest drugs applied in 
some European countries.
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OBJECTIVES: To approve a public price for a drug in Jordan, Jordan food and Drug 
association (JFDA) drug pricing committee ought to review the lowest price in the 
country of origin, the price of a predefined 13 countries and in KSA. In 2012, the 
evidence of cost-effectiveness (CE) was required to inform decisions of drug pricing. 
We sought to assess the role of CE studies in pricing drugs in Jordan. METHODS: A 
retrospective review of all applications submitted to the JFDA between November 
2013 to January 2015. RESULTS: The committee reviewed a total of 1,608 drug pric-
ing requests. Two hundred four were ricing new drugs, 369 were pricing local and 
international generics. The remainder was for pricing drugs previously registered in 
Jordan but renewed periodically as per policy. There was 11 enquires involving the 
use of CE studies. Applicants failed to correspond adequately to the committee and 
the committee often reconfirmed the requests more than one time. Median (IQR) 
of correspondences was 2 (3) times per case. These studies were non-comparative 
and concerning with establishing clinical efficacy. Median (IQR) ratio of the price 
proposed by applicants to the price of comparable substitute(s) was 1.7 (1.5). The 
prices were always negotiated downwards close to the price of the available sub-
stitutes. A premium price (i.e. +10% to 20%) was advocated to reward for added 
benefits such as convenience. CONCLUSIONS: The Jordanian pricing policies are 
comprehensive in responding to most of drug pricing applications. Decisions are 
straightforward with most comparisons made between drugs having similar clinical 
profiles. However, where CE evidence required there is no formal decision rules laid 
down, thus an official set of decision tools is warranted. This would include details 
of the perspective to be adopted, the comparisons to be made, form of economic 
evaluation and sources of data.
PHP19
tHe difference between tHe maximum retail Price and tender Price: 
a comParative study on brandname and generic drugs
Liu B.
Department of Health Economics, School of Public Health, Fudan University, Shanghai, China
OBJECTIVES: To compare the difference between the maximum retail price and 
tender price of brandname and generic drugs. METHODS: A large database analysis 
was used. The database was formed by merging two sub-databases, one was the 
tender prices of 94 antimicrobial drugs and circulatory system drugs collected from 
the centralized tendering of drug purchases across all the provinces(autonomous 
regions, municipality directly under the central government) of mainland China over 
the period of 2005-2013, the other was the corresponding maximum retail prices 
issued by the National Development and Reform Commission of China. The per-
centage differences between the maximum retail price and tender price (provincial 
average) was then calculated by year for antimicrobial drugs and circulatory system 
drugs, respectively. The generic-brandname ratio of the concerned percentage differ-
ences was also calculated. RESULTS: The percentage difference between maximum 
retail price and tender price for generic drugs was large, while the corresponding 
difference in brandname drugs was much smaller. The generic-brandname ratio 
of the concerned percentage differences increased from 1.7 in 2005 to 5.7 in 2013, 
except a mild decrease in 2009 and a moderate decrease in 2012. CONCLUSIONS: 
It may be the time to lift price control on drugs in China since the maximum retail 
price issued by the national government was too high as compared with tender 
price to exert effect on generic drugs, while for brandname drugs the maximum 
retail price was too close to tender price, which also consequentially diluted the 
significance of maximum retail price.  KEYWORDS: Maximum retail price; Tender 
price; Price reform; large database analysis. 
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OBJECTIVES: Canada has established Patented Medicine Prices Review Board 
(PMPRB) in 1987 with the objective of regulating prices of patented medicines sold 
in Canada to ensure prices are not excessive. When drugs’ prices meet the guide-
lines, they will be accepted; otherwise, the sponsor company will decrease them. The 
Employee Basic Medical Insurance (UEBMI) claims of Tianjin city from April 2008 
to March 2010 were used to compare the patients’ outpatient visit, total spending, 
drug spending, and OOP spending before and after the implementation of the EMP. 
The intervention group consisted of patients who visit the primary care institu-
tion which implemented EMP at least once before and after EMP and did not visit 
the control primary care institution which did not implement EMP, vice versa for 
the control group. A difference-in-difference approach was used to estimate the 
effects adjusting for patients’ socio-demographic characteristics and disease sever-
ity. Negative binomial regression was used to estimate the outpatient visit and tobit 
model was used to estimate the cost. RESULTS: Totally, 23362 patients from 49 
interventional primary care institution and 4148 patients from 42 control institution 
were involved in the study. The regression results showed that the annual patients’ 
outpatient visits (0.5%, p= 0.791) and the visits to primary care institution (0.2%, 
p= 0.951) had no change after implementing EMP compared to the control group. 
The patient’s average total spending (-0.6%, p= 0.850), drug spending (1.6%, p= 0.703) 
and OOP spending (0.4%, p= 0.883) did not change. The average total spending (2.9%, 
p= 0.443), drug spending (1.9%, p= 0.724) and OOP spending (1.2%, p= 0.722) in primary 
care institution was also not changed after implementing EMP. CONCLUSIONS: The 
EMP in Tianjin China was not associated with more outpatient visits in primary care 
institution and less medical spending, drug spending and OOP spending.
PHP14
imPact of 2014 essential HealtH benefit bencHmarK Plans on us 
managed care
Aggarwal S., Topaloglu H.
NOVEL Health Strategies, Chevy Chase, MD, USA
OBJECTIVES: Beginning in 2014, the Affordable Care Act requires new health plans to 
cover essential health benefits (EHB), including pharmaceutical products, according 
to the state level benchmark plans. The objectives of this analysis were to understand 
state level variations in design of plans, access to drugs and likely impact on patient 
choice and health outcomes. METHODS: Benchmark plans for the top five states 
(i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were obtained from the CMS. 
For each plan, the categories, classes and number of covered drugs was collected and 
pooled into one database. Analysis was conducted at the entire population level, state-
level and for top classes of drugs. The comments from patient groups were reviewed 
to understand the impact of EHB on patient choice and health outcomes. RESULTS: 
Benchmark plans for the top five states provide coverage of 4215 drugs belonging 
to 158 classes as defined by USP. While four states (FL, IL, NY and TX) had a similar 
number of covered drugs (median of 892 drugs), CA had a significantly lower number 
of covered drugs, amounting to 28% less than the other four states. On average, 10% 
of the drugs were in the class called “No USP Class”, highlighting the limitation of 
CMS designated USP classification system for the new plans. In CA, FL, IL, NY and 
TX there were 18, 7, 8, 11 and 8 classes, respectively, for which only 1 was covered. 
In CA, top 8 classes were identified for which patients had a 75% lower choice than 
other states, and these included indications such as Anti-Diabetics and Pain medi-
cations. CONCLUSIONS: Review of new benchmark plans shows some states can 
have a significantly lower patient choice of therapies. There is a need for new policy 
measures to ensure that all patients have equal access to new treatments.
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OBJECTIVES: Therapeutic biologic products (BLA) are produced in living cell cul-
tures or through genetic engineering of proteins. The FDA BLA definition excludes 
allergenics, blood products, cellular and gene therapy, tissue products, and vaccines. 
This study assessed trends in BLAs licensed by the FDA and the European Medicines 
Agency (EMA) in the period 1995-2014. METHODS: Regulatory information for BLAs 
was derived from the agencies webpages. We extracted data for BLAs approved 
before the establishment of the EMA licensing process from the UK Medicines and 
Healthcare products Regulatory Agency (MHRA). Insulins and some hormones that are 
approved by the FDA using the drug application system, were excluded from analysis. 
BLA were classified using the WHO anatomical therapeutic chemical classification. 
Descriptive statistics and chi-square tests were conducted in the study. RESULTS: 115 
BLA were licensed by the FDA and the EMA in the period 1995-2014. The FDA licensed 
85.2% and the EMA 73.0% of the BLAs (p< 0.0001), with 22.6% of the BLAs licensed only 
by the FDA and 14.8% by the EMA. There were 5 BLA licensed by MHRA and the FDA. 
The EMA refused to license 4 BLAs. There were 62 BLAs (53.9% of the total) licensed by 
both agencies. The FDA licensed first 79.0% of the BLAs and the EMA 21.0%. The FDA 
licensed the BLAs in a median of 181 days before than the EMA. The largest number 
of BLAs corresponded to antineoplastic and immunomodulating agents (48.7% of 
BLAs), blood and blood forming organs (13.0%), and alimentary tract and metabolism 
(9.6%). CONCLUSIONS: The study found differences in the number of BLAs licensed 
by the FDA and the EMA. The FDA approved faster and licensed significantly more 
BLAs than the EMA. Future research should evaluate the effect in patient outcomes 
and cost of differences in BLAS availability in US and Europe.
PHP17
tHe imPact of new drug Pricing Policy on marKet comPetition 
among off-Patent drugs in soutH Korea
Kwon H.1, Kim H.2, R. Reich M.1
1Harvard T.H. Chan School of Public Health, Boston, MA, USA, 2National Health Insurance Service, 
Seoul, South Korea
OBJECTIVES: This study aims to evaluate the impact of the new pricing policy 
implemented as of April, 2012 in South Korea on market competition among 
off-patent drugs since the reform has taken an objective to introduce market 
competition mechanisms among off-patent drugs. According to the new pricing 
